A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps (webcourse)

Format: Webcourse
Credit(s): 1.00 (60 min)
Release Date: Sep 30, 2022
Expiration Date: Sep 30, 2023
Credit Type(s):
  • Physicians – AMA PRA Category 1 Credit(s) ™
  • Physicians – prescribed AAFP Credit(s)
  • Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

Chronic rhinosinusitis with nasal polyps (CRSwNP) is the most common cause of nasal polyposis, and approximately one third of patients with chronic rhinosinusitis (CRS) will develop nasal polyps. CRSwNP is associated with significant morbidity and negative impacts on patient quality of life, making rapid diagnosis and treatment highly important. Until recently, treatment for CRSwNP has included topical therapy, systemic corticosteroids, and surgery, with minimal efficacy and high morbidity. However, improved understanding of the pathophysiology of CRSwNP has led to the development of numerous biologic therapies that target the inflammatory pathways underlying disease pathogenesis. These agents are more effective and less toxic than historic treatments.

This activity, A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps will review the major causes of nasal polyps and how to diagnose CRSwNP, the pathophysiology of CRSwNP, the safety and efficacy of approved treatment options that target the underlying pathophysiology of CRSwNP, and new agents on the horizon.

PROVIDER

Jointly provided by

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

RELATED COURSES

CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer (Grand Rounds)

Learn More

Personalized Approaches to HER2-Positive Breast Cancer Treatment (webcourse)

Learn More

A Breath of Fresh Air: New Treatment Strategies for Chronic Rhinosinusitis with Nasal Polyps

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy